How Does Ivabradine Work for POTS? Uses & Side Effects
At a Glance
Ivabradine treats POTS by blocking the funny current in the heart's pacemaker cells to slow a racing heart. Unlike beta-blockers, it lowers your heart rate without dropping blood pressure or reducing pumping strength, making it ideal for patients prone to fatigue and dizziness.
Ivabradine is a medication frequently prescribed off-label for Postural Orthostatic Tachycardia Syndrome (POTS) that works by specifically targeting the electrical signals in your heart’s natural pacemaker. Unlike many other heart rate medications, it successfully slows a racing heart rate without lowering your blood pressure or causing the severe fatigue often associated with other treatments [1][2]. It achieves this by selectively blocking a specific electrical channel in the heart, making it a highly effective alternative for POTS patients who cannot tolerate traditional, first-line medications [3][4].
Because it is prescribed “off-label” (meaning it is FDA-approved for heart failure but used in POTS based on strong clinical evidence), patients often need to work closely with their doctor’s office to navigate insurance coverage. This can sometimes involve prior authorizations or exploring alternative pharmacy options if out-of-pocket costs are high.
Targeting the Heart’s Pacemaker
Your heart rate is controlled by the sinoatrial (SA) node, a cluster of specialized cells that act as the heart’s natural pacemaker. Inside these cells is an electrical channel that carries what cardiologists playfully call the “funny current” (often written as
Ivabradine works by binding to these specific channels and selectively blocking the funny current [5][7]. By slowing down this electrical current, it takes slightly longer for the pacemaker cells to trigger the next beat, which effectively lowers your overall heart rate [6][7].
How Ivabradine Differs From Beta-Blockers
The most common first-line medications prescribed for POTS are beta-blockers, which slow the heart rate by blocking adrenaline receptors. However, beta-blockers also reduce how hard the heart muscle squeezes and can widen blood vessels, which often leads to a drop in blood pressure [1][2]. For many POTS patients who already struggle with low blood pressure or poor blood circulation to the brain, beta-blockers can worsen symptoms like severe fatigue, dizziness, and “brain fog.”
Ivabradine provides two distinct advantages for POTS patients:
- It is blood pressure-neutral: Because it does not affect the size of blood vessels, ivabradine lowers the heart rate without dropping systemic blood pressure [1][2]. Any stabilization or slight elevation in blood pressure seen in some patients is an indirect benefit of giving the heart more time to fill with blood between beats [8].
- It preserves heart contractility: Ivabradine does not reduce the physical pumping strength of the heart muscle [1][9]. This ensures that your body and brain continue to receive a strong, steady flow of oxygenated blood.
Safety, Side Effects, and Practicalities
While clinical trials show ivabradine is generally well-tolerated in POTS patients [3][10], it is important to be aware of its specific safety profile:
- Phosphenes (Visual Changes): A unique side effect of ivabradine is the occurrence of phosphenes—transient, luminous visual spots or enhanced brightness in your field of vision [11][12]. These are typically harmless and often resolve over time, but you should still report them to your doctor.
- Heart Rate & Rhythm: Because it slows the heart, there is a risk of bradycardia (excessively slow heart rate) causing dizziness, though this was not significant in POTS-specific studies [3][13]. There is also a small risk of new-onset atrial fibrillation [14].
- Contraindications: Ivabradine interacts with certain medications, including specific antifungals or antibiotics [15]. It is also not suitable for patients with severe liver issues or certain pre-existing heart rhythm problems, and it is strictly contraindicated during pregnancy due to potential fetal risks [13][16].
How it is taken: Ivabradine is typically taken as a pill twice daily. Doctors generally recommend taking it with meals, as food ensures consistent absorption of the medication into your bloodstream [12].
Improvements in POTS Symptoms
Controlling excessive heart rate with ivabradine can translate directly into a better quality of life. Research involving hyperadrenergic POTS patients demonstrated that one month of ivabradine treatment significantly reduced standing heart rates compared to a placebo [3]. Patients treated with ivabradine frequently report significant improvements in both their physical functioning and their ability to participate in social activities [3][17]. For those who have failed or cannot tolerate conventional therapies, ivabradine represents a highly effective, targeted option for symptom relief [18][4].
Common questions in this guide
How is ivabradine different from beta-blockers for POTS?
Why is ivabradine prescribed off-label for POTS?
What are the common side effects of taking ivabradine?
How do I take ivabradine for POTS?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does my specific presentation of POTS (e.g., hyperadrenergic vs. neuropathic) make me a good candidate for ivabradine?
- 2.What should I expect regarding my heart rate while taking this, and what is my target resting and standing rate?
- 3.Are there any medications or supplements I currently take that might interact with ivabradine or affect how it is absorbed?
- 4.What is our backup plan if my insurance denies the off-label coverage for this medication?
- 5.What should I do if I experience visual side effects like bright spots (phosphenes) or feel dizzy from a slow heart rate?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (18)
- 1
Ivabradine and the SIGNIFY conundrum.
Beltrame JF
European heart journal 2015; (36(46)):3297-9 doi:10.1093/eurheartj/ehv368.
PMID: 26264551 - 2
Heart Rate Control during Experimental Sepsis in Mice: Comparison of Ivabradine and β-Blockers.
Bedet A, Voiriot G, Ternacle J, et al.
Anesthesiology 2020; (132(2)):321-329 doi:10.1097/ALN.0000000000003045.
PMID: 31939847 - 3
Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome.
Taub PR, Zadourian A, Lo HC, et al.
Journal of the American College of Cardiology 2021; (77(7)):861-871 doi:10.1016/j.jacc.2020.12.029.
PMID: 33602468 - 4
Postural Tachycardia Syndrome and COVID-19: Focus on Ivabradine Therapy.
Dixit K, Frishman WH
Cardiology in review 2024; (32(3)):279-284 doi:10.1097/CRD.0000000000000503.
PMID: 36729924 - 5
Role of the Funny Current Inhibitor Ivabradine in Cardiac Pharmacotherapy: A Systematic Review.
Petite SE, Bishop BM, Mauro VF
American journal of therapeutics 2018; (25(2)):e247-e266 doi:10.1097/MJT.0000000000000388.
PMID: 26910057 - 6
The hyperpolarization-activated cyclic nucleotide-gated channel currents contribute to oxaliplatin-induced hyperexcitability of DRG neurons.
Yongning Z, Xianguang L, Hengling C, et al.
Somatosensory & motor research 2021; (38(1)):11-19 doi:10.1080/08990220.2020.1834376.
PMID: 33092457 - 7
The Clinical Use of Ivabradine.
Koruth JS, Lala A, Pinney S, et al.
Journal of the American College of Cardiology 2017; (70(14)):1777-1784 doi:10.1016/j.jacc.2017.08.038.
PMID: 28958335 - 8
A Randomized Crossover Trial of Ivabradine, Propranolol, and Placebo in Postural Orthostatic Tachycardia Syndrome: A Detailed Description.
Uppal J, Deol P, Giri P, et al.
JACC. Advances 2026; (5(6 Pt 2)):102795 doi:10.1016/j.jacadv.2026.102795.
PMID: 42132710 - 9
Ivabradine in Septic Shock: A Narrative Review.
Pasetto M, Calabrò LA, Annoni F, et al.
Journal of clinical medicine 2024; (13(8)) doi:10.3390/jcm13082338.
PMID: 38673611 - 10
The Effect of Ivabradine on the Heart Rate and Sympathovagal Balance in Postural Tachycardia Syndrome Patients.
Barzilai M, Jacob G
Rambam Maimonides medical journal 2015; (6(3)) doi:10.5041/RMMJ.10213.
PMID: 26241226 - 11
Ivabradine in Postural Orthostatic Tachycardia Syndrome: Preliminary Experience in Children.
Delle Donne G, Rosés Noguer F, Till J, et al.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2018; (18(1)):59-63 doi:10.1007/s40256-017-0248-x.
PMID: 29027608 - 12
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K, Komajda M, Böhm M, et al.
Lancet (London, England) 2010; (376(9744)):875-85 doi:10.1016/S0140-6736(10)61198-1.
PMID: 20801500 - 13
Ivabradine toxicity: a case report.
Singh K, Alagarraju MR, Wolf CE, et al.
Journal of medical case reports 2022; (16(1)):392 doi:10.1186/s13256-022-03554-w.
PMID: 36274174 - 14
Reassessing Ivabradine: Potential Benefits and Risks in Atrial Fibrillation Therapy.
Alijanzadeh D, Moghim S, Zarand P, et al.
Cardiovascular drugs and therapy 2025; (39(6)):1567-1584 doi:10.1007/s10557-024-07652-3.
PMID: 39656365 - 15
Influence of Ivabradine on the Anticonvulsant Action of Four Classical Antiepileptic Drugs Against Maximal Electroshock-Induced Seizures in Mice.
Sawicka KM, Wawryniuk A, Zwolak A, et al.
Neurochemical research 2017; (42(4)):1038-1043 doi:10.1007/s11064-016-2136-1.
PMID: 28083847 - 16
Ivabradine toxicity: A case report and review.
Osei K, Taskesen T, Goerbig-Campbell J, Hounshell T
HeartRhythm case reports 2020; (6(4)):183-186 doi:10.1016/j.hrcr.2019.12.007.
PMID: 32322492 - 17
Ivabradine in children with postural orthostatic tachycardia syndrome: a retrospective study.
Towheed A, Nesheiwat Z, Mangi MA, et al.
Cardiology in the young 2020; (30(7)):975-979 doi:10.1017/S1047951120001341.
PMID: 32498748 - 18
Effect of Ivabradine on Heart Failure: A 2024 Meta-Analysis.
Maharaj A, Maturasingh MB, Khangembam A, et al.
Cureus 2025; (17(1)):e77346 doi:10.7759/cureus.77346.
PMID: 39944426
This page is for informational purposes only and does not replace professional medical advice. Always consult your cardiologist or healthcare provider regarding POTS treatment options and medication management.
Get notified when new evidence is published on Postural Orthostatic Tachycardia Syndrome (POTS).
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.